美容护理行业周报：关注业绩表现亮眼标的

Investment Rating - The industry investment rating is "Overweight (Maintain)" [4][8] Core Viewpoints - The medical aesthetics sector continues to show high prosperity, with collagen products maintaining strong growth, particularly the AestheFill youth injection [4][8] - Companies like Jinbo Biological and Jiangsu Wuzhong are experiencing significant revenue growth, with Jinbo achieving a revenue of 386 million yuan in Q3 2024, up 92.07% year-on-year, and Jiangsu Wuzhong turning profitable with a revenue of 441 million yuan, up 9.46% year-on-year [5][6] - The beauty segment is seeing a focus on leading brands and cost-effective products, with Proya achieving a revenue of 1.965 billion yuan in Q3 2024, up 21.15% year-on-year [6][8] Summary by Relevant Sections Medical Aesthetics - Jinbo Biological reported a Q3 2024 revenue of 386 million yuan, a year-on-year increase of 92.07%, with a net profit of 210 million yuan, up 153.96% [4][5] - Jiangsu Wuzhong's Q3 2024 revenue reached 441 million yuan, a 9.46% increase year-on-year, with a net profit of 21 million yuan, marking a return to profitability [5] - Aesthetic products like AestheFill are expected to continue gaining market share [8] Beauty Products - Proya's Q3 2024 revenue was 1.965 billion yuan, reflecting a 21.15% year-on-year growth, with a net profit of 298 million yuan, up 20.72% [6] - Runben's Q3 2024 revenue reached 293 million yuan, a 20.10% increase year-on-year, with a net profit of 81 million yuan, up 31.98% [6] - The beauty market is characterized by increasing competition among brands, with top domestic brands expected to maintain their leading positions [8]